[Single nucleotide polymorphism and novel drug discovery].
The finding of genetic polymorphisms and clarification of the influences of their functions will be a possible way to obtain the therapeutic target moleculars for diseases. In clinical trial of new drug, which is targeted the therapeutic molecular, the gene examination will be needed to classify possible responder and unresponder patients. On the other hand, it is important to make effort on the elimination of candidate drugs, their pharmacokientic and metabolism, clinical efficacy and toxicity will be markedly influenced by genetic polymorphism.
Kato
Ryuichi
R
School of Medicine, Keio University.
D000483:Alleles; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics / Q000378:metabolism; D044466:Asian People / Q000235:genetics; D065729:Cytochrome P-450 CYP2C9; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism; D016903:Drug Monitoring; D006801:Humans; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D044465:White People / Q000235:genetics
C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D019389:Cytochrome P-450 CYP2D6